Singapore markets closed

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
152.34+2.89 (+1.93%)
At close: 04:03PM EDT
152.57 +0.23 (+0.15%)
After hours: 07:51PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close149.45
Open150.89
Bid151.61 x 1000
Ask152.17 x 800
Day's range149.62 - 152.74
52-week range105.56 - 175.91
Volume7,902,775
Avg. volume7,338,458
Market cap269.202B
Beta (5Y monthly)0.81
PE ratio (TTM)21.85
EPS (TTM)6.97
Earnings date28 Jul 2022 - 01 Aug 2022
Forward dividend & yield5.64 (4.08%)
Ex-dividend date14 Apr 2022
1y target est163.01
  • Zacks

    Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates

    The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).

  • Motley Fool

    Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip

    As prices go down, yields go up, and that dynamic has made both Target (NYSE: TGT) and AbbVie (NYSE: ABBV) excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks. For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble.

  • Zacks

    AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention

    With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.